Ryan J Sullivan

Ryan J Sullivan

UNVERIFIED PROFILE

Are you Ryan J Sullivan?   Register this Author

Register author
Ryan J Sullivan

Ryan J Sullivan

Publications by authors named "Ryan J Sullivan"

Are you Ryan J Sullivan?   Register this Author

100Publications

3976Reads

-Profile Views

High Throughput Strategies for the Discovery and Optimization of Catalytic Reactions.

Angew Chem Int Ed Engl 2019 May 12;58(22):7180-7191. Epub 2019 Mar 12.

Centre for Catalysis Research and Innovation, Department of Chemistry and Biomolecular Sciences, University of Ottawa, 10 Marie-Curie, Ottawa, Ontario, K1N 6N5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.201812534DOI Listing
May 2019

What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.

Oncology (Williston Park) 2019 04;33(4):141-8

View Article

Download full-text PDF

Source
April 2019

Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.

Clin Cancer Res 2019 Apr 16. Epub 2019 Apr 16.

Center for Melanoma, Massachusetts General Hospital Cancer Center

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0836DOI Listing
April 2019

Mechanisms of Resistance to Immune Checkpoint Blockade.

Am J Clin Dermatol 2019 Feb;20(1):41-54

Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 7E, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0389-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358473PMC
February 2019

The future of combination treatment with checkpoint inhibitors in melanoma.

Authors:
Ryan J Sullivan

Clin Adv Hematol Oncol 2019 Feb;17(2):96-99

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
February 2019

Frontline Therapy for -Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:564-571. Epub 2019 May 17.

4 Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_243071DOI Listing
January 2019

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Nat Med 2018 Dec;24(12):1942

Center for Bioinformatics and Computational Biology, Department of Computer Science, University of Maryland, College Park, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-018-0247-8DOI Listing
December 2018

Reply to emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes.

Cancer 2018 Dec 23;124(24):4732. Epub 2018 Oct 23.

Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31786
Publisher Site
http://dx.doi.org/10.1002/cncr.31786DOI Listing
December 2018

Forestalling BRAF-Inhibitor Resistance in a Shocking Way.

Authors:
Ryan J Sullivan

Clin Cancer Res 2018 Nov 6;24(22):5496-5498. Epub 2018 Jul 6.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1344DOI Listing
November 2018

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Nat Med 2018 10 20;24(10):1545-1549. Epub 2018 Aug 20.

Center for Bioinformatics and Computational Biology, Department of Computer Science, University of Maryland, College Park, MD, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41591-018-0157-9
Publisher Site
http://dx.doi.org/10.1038/s41591-018-0157-9DOI Listing
October 2018

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

Semin Arthritis Rheum 2018 Oct 16. Epub 2018 Oct 16.

Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00490172183044
Publisher Site
http://dx.doi.org/10.1016/j.semarthrit.2018.10.012DOI Listing
October 2018

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.

Cancer 2018 Sep 5;124(18):3706-3714. Epub 2018 Jul 5.

Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31629DOI Listing
September 2018

Keeping Expectations in Check With Immune Checkpoint Inhibitors.

J Clin Oncol 2018 Jun 25;36(17):1654-1657. Epub 2018 Jan 25.

Jennifer S. Temel, Justin F. Gainor, Ryan J. Sullivan, and Joseph A. Greer, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2146DOI Listing
June 2018

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.

J Neurooncol 2018 Jun 16;138(2):299-306. Epub 2018 Feb 16.

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 30 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2795-7DOI Listing
June 2018

The role of targeted therapy for melanoma in the immunotherapy era.

Authors:
Ryan J Sullivan

Semin Cutan Med Surg 2018 Jun;37(2):112-119

Center for Melanoma, MGH Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12788/j.sder.2018.021DOI Listing
June 2018

Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges.

Authors:
Ryan J Sullivan

Cancer Discov 2018 May;8(5):532-533

Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0224DOI Listing
May 2018

Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.

Radiographics 2017 Nov-Dec;37(7):2132-2144

From the Departments of Radiology (G.X.W., V.K., S.I.L., F.J.F.) and Medicine (J.F.G., R.J.S., K.T.F.), Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Founders 210, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.2017170085DOI Listing
April 2018

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

J Am Coll Cardiol 2018 Apr 19;71(16):1755-1764. Epub 2018 Mar 19.

Cardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.02.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196725PMC
April 2018

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

J Transl Med 2018 04 17;16(1):101. Epub 2018 Apr 17.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-018-1477-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905181PMC
April 2018

Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.

Future Oncol 2017 Aug 4;13(18):1649-1663. Epub 2017 Aug 4.

Department of Medicine, Massachusetts General Hospital & Harvard Medical School,  Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0117DOI Listing
August 2017

The evolutionary nature of the cancer immunotherapy revolution.

Authors:
Ryan J Sullivan

Future Oncol 2017 08 22;13(18):1565-1567. Epub 2017 Aug 22.

Massachusetts General Hospital & Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0232DOI Listing
August 2017

Immune checkpoint inhibitors in challenging populations.

Cancer 2017 06 27;123(11):1904-1911. Epub 2017 Feb 27.

Department of Medicine, Melanoma Institute Australia, University of Sydney Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445005PMC
June 2017

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

J Immunother 2017 04;40(3):108-113

*Massachusetts General Hospital Cancer Center †Department of Radiology, Massachusetts General Hospital, Harvard Medical School ‡Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000159DOI Listing
April 2017

Are we entering the era of combination therapy for melanoma?

Melanoma Manag 2017 Mar 1;4(1):5-8. Epub 2017 Mar 1.

Cancer Center - Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2016-0029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094618PMC
March 2017

Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.

Clin Cancer Res 2017 Feb 28;23(3):623-629. Epub 2016 Nov 28.

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290119PMC
February 2017

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

J Immunother 2017 01;40(1):31-35

*Vanderbilt University Medical Center, Nashville, TN †Beth Israel Deaconess Medical Center ‡Dana-Farber Cancer Institute §Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/immunotherapy-journal/2017/0100
Web Search
http://dx.doi.org/10.1097/CJI.0000000000000148DOI Listing
January 2017

Inherent vs Apparent Chemoselectivity in the Kumada-Corriu Cross-Coupling Reaction.

Org Lett 2016 Oct 4;18(20):5312-5315. Epub 2016 Oct 4.

Centre for Catalysis Research and Innovation, Department of Chemistry and Biomolecular Sciences, University of Ottawa , 10 Marie-Curie, Ottawa, Ontario, Canada , K1N 6N5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.orglett.6b02631DOI Listing
October 2016

Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy.

Oncologist 2016 09 7;21(9):1136-7. Epub 2016 Jul 7.

Harvard University, Cambridge, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016073PMC
September 2016

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.

Nat Med 2016 09 8;22(9):1056-61. Epub 2016 Aug 8.

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014622PMC
September 2016

Melanoma driver mutations and immune therapy.

Oncoimmunology 2016 May 10;5(5):e1051299. Epub 2016 Mar 10.

Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center , Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1051299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910708PMC
May 2016

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.

Cancer Discov 2016 Apr 16;6(4):382-99. Epub 2016 Mar 16.

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087317PMC
http://dx.doi.org/10.1158/2159-8290.CD-15-0933DOI Listing
April 2016

The role of mitogen-activated protein targeting in melanoma beyond BRAFV600.

Authors:
Ryan J Sullivan

Curr Opin Oncol 2016 Mar;28(2):185-91

Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000271DOI Listing
March 2016

mutant melanoma: an overview for the clinician for melanoma management.

Melanoma Manag 2016 Mar 17;3(1):47-59. Epub 2016 Feb 17.

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097550PMC
March 2016

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

J Natl Cancer Inst 2016 Feb 23;108(2). Epub 2015 Oct 23.

Department of Medicine (PKB, RS), Department of Neurology (PKB, CMG), Department of Neurosurgery (GMS, PJ, BN, DPC, WTC, FGB), Department of Surgical Oncology (DTF), Department of Pathology (GG, DNL), Cancer Center (PKB, CMG, NN, DNL), Department of Radiology (JR) Massachusetts General Hospital, Harvard Medical School, Boston, MA; Broad Institute (ATW, GG), Department of Pathology, (MA, SS) and Department of Neurosurgery, Brigham and Women's Hospital (IFD), Boston, MA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (DJP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862417PMC
February 2016

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.

Am J Clin Dermatol 2016 Feb;17(1):1-10

Center for Melanoma, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-015-0159-z
Publisher Site
http://dx.doi.org/10.1007/s40257-015-0159-zDOI Listing
February 2016

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.

Oncotarget 2015 Dec;6(38):40535-56

Department of Biomedical Sciences and Cancer Biology Center, Texas Tech University Health Sciences Center, Amarillo, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747351PMC
December 2015

Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.

Nat Rev Clin Oncol 2015 Nov 29;12(11):625-6. Epub 2015 Sep 29.

Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.170DOI Listing
November 2015

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

Semin Oncol 2015 Aug 3;42(4):601-16. Epub 2015 Jun 3.

Department of Medical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754150010
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2015.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955940PMC
August 2015

Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.

Clin Cancer Res 2015 Jul 30;21(13):2892-7. Epub 2015 Apr 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3061DOI Listing
July 2015

New strategies in melanoma: entering the era of combinatorial therapy.

Clin Cancer Res 2015 Jun;21(11):2424-35

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1650DOI Listing
June 2015

Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.

J Neurooncol 2015 May 12;123(1):75-84. Epub 2015 Apr 12.

Harvard Radiation Oncology Program, 75 Francis Street, ASB1, L2, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1761-xDOI Listing
May 2015

Optimal treatment selection for patients with metastatic melanoma.

Authors:
Ryan J Sullivan

Oncology (Williston Park) 2015 Feb;29(2):139-41

View Article

Download full-text PDF

Source
February 2015

Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.

Expert Rev Clin Pharmacol 2015 Jan 4;8(1):25-33. Epub 2014 Dec 4.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2015.974556DOI Listing
January 2015

Biomarkers in melanoma: where are we now?

Melanoma Manag 2014 Nov 4;1(2):139-150. Epub 2014 Dec 4.

Department of Medicine, Division of Hematology/Oncology Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.14.19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094630PMC
November 2014

Emerging clinical issues in melanoma in the molecularly targeted era.

Methods Mol Biol 2014 ;1102:11-26

Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-727-3_2DOI Listing
June 2014

Assaying for BRAF V600E in tissue and blood in melanoma.

Methods Mol Biol 2014 ;1102:117-36

Beth Israel Deaconess Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-727-3_8DOI Listing
June 2014

Understanding the biology of melanoma and therapeutic implications.

Hematol Oncol Clin North Am 2014 Jun;28(3):437-53

Department of Dermatology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Bartlett 6, 55 Fruit Street, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.02.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116747PMC
June 2014

Isolation and molecular characterization of circulating melanoma cells.

Cell Rep 2014 May 18;7(3):645-53. Epub 2014 Apr 18.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Howard Hughes Medical Institute, Bethesda, MD 20815, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.cell.com/cell-reports/pdf/S2211-1247(14)00217-4.p
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S221112471400217
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2014.03.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079008PMC
May 2014

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Cancer Discov 2014 Jan 21;4(1):61-8. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947296PMC
January 2014

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

Clin Cancer Res 2013 Oct;19(19):5283-91

Authors' Affiliations: Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts; and Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100326PMC
October 2013

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.

Oncoimmunology 2013 Oct 15;2(10):e26615. Epub 2013 Oct 15.

Department of Surgical Oncology; University of Texas MD Anderson Cancer Center; Houston, TX USA ; Department of Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston, TX USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.26615
Publisher Site
http://dx.doi.org/10.4161/onci.26615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827093PMC
October 2013

Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.

N Engl J Med 2013 Jul;369(2):173-83

Department of Medicine, Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcpc1302332DOI Listing
July 2013